Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triapine in Uterine Corpus Serous Adenocarcinoma
NCT04494113Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2022
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of triapine in endometrial serous carcinoma (ESC), sponsored by National Cancer Institute. Primary endpoint: Pharmacodynamic response. Started Feb 2022; status: active, not recruiting.
02
Drugs
triapine
03
Conditions
endometrial serous carcinoma (ESC)
Beyond the preview
Go deeper on NCT04494113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04494113.